Association of <i>Clostridium butyricum</i> Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations

Association of <i>Clostridium butyricum</i> Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations

The gut microbiota has emerged as a key regulator of immune checkpoint inhibitor (ICI) efficacy. Therapeutic approaches aimed at manipulating the microbiota through targeted reconstitution to enhance cancer treatment outcomes have garnered considerable attention. A single live microbial biotherapeut...

Full description

Bibliographic Details
Main Authors: Yusuke Tomita, Shinya Sakata, Kosuke Imamura, Shinji Iyama, Takayuki Jodai, Koichi Saruwatari, Shohei Hamada, Kimitaka Akaike, Moriyasu Anai, Kazuaki Fukusima, Akira Takaki, Hirotake Tsukamoto, Yoshihiko Goto, Chihiro Motozono, Kenji Sugata, Yorifumi Satou, Takamasa Ueno, Tokunori Ikeda, Takuro Sakagami
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
antibiotics
CBM588
dysbiosis
gut microbiome
immune checkpoint inhibitor
<i>Clostridium butyricum</i>
Online Access:https://www.mdpi.com/2072-6694/16/1/47

Internet

https://www.mdpi.com/2072-6694/16/1/47

Similar Items